Syngene International Limited — PPTs, 23-01-2026: Investor Presentation

Syngene's Q3 FY26 revenue dipped slightly to Rs 91.71 Cr, down 3% YoY, while profit (PAT ex-items) fell significantly by 44% to Rs 7.29 Cr. For the nine months, revenue saw modest 3% growth to Rs 270.22 Cr, but profit declined 22% to Rs 22.67 Cr. Operating EBITDA margins were compressed to 23% for both periods.

The company is strategically focusing on expanding its integrated CRDMO platform across small and large molecule discovery, development, and manufacturing. Digital transformation, including AI adoption, is a key enabler for future growth and operational efficiency.

A major recent win includes the extension of its long-standing partnership with Bristol Myers Squibb (BMS) through 2035, broadening service scope. Syngene also commissioned a new commercial-scale liquid-filled hard gelatin capsule facility and expanded advanced chemistry labs in Hyderabad.

Management highlights a commitment to operational excellence, fostering a high-performance organization, and sustainable growth. The goal is to establish fully integrated, cutting-edge development and manufacturing services for both small and large molecules, alongside end-to-end therapeutic discovery services.